Skip to main content
European Commission logo
Enterprise Europe Network

Search for a partner (public institution/hospital/clinical expert) specialized in Parkinson's disease for the EU's Joint Research Program on Neurodegenerative Diseases (JPND)

Summary

Profile Type
  • Research & Development Request
POD Reference
RDRFR20250214019
Term of Validity
14 February 2025 - 14 February 2026
Company's Country
  • France
Type of partnership
  • Research and development cooperation agreement
Targeted Countries
  • All countries
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
A French start-up and a renowned Canadian laboratory are looking for a third partner for the EU's Joint Program for Research into Neurodegenerative Diseases (JPND). The aim is to achieve proof-of-concept of the combined technologies of the startup and the Canadian laboratory by validating the results in practical cases with Parkinson's disease clinical experts. The partner's role will be to validate the results of the algorithms and help them improve medical recommendations.
Full Description
A third partner is sought to join an ambitious European research initiative focusing on neurodegenerative diseases in their moderate to late stages. The project aims to integrate cutting-edge AI-driven pharmacological modeling and federated learning-based neuroinformatics to improve treatment strategies for Parkinson's disease.

Despite significant advancements in artificial intelligence (AI) for healthcare, there remains a critical gap between pharmacological research and clinical decision support systems for neurodegenerative diseases. By leveraging their expertise in pharmacodynamics alongside the federated neuroinformatics platform developed by a renowned Canadian institution, they aim to create a robust AI-driven tool designed to optimize treatment strategies for Parkinson's disease in its moderate to late stages.

Programme Framework Conditions: This project is intended for submission under the EU Joint Programme – Neurodegenerative Disease Research (JPND) or Horizon Europe 2030, both of which support interdisciplinary research aimed at improving patient outcomes.

To comply with JPND consortium requirements, the French start-up and the renowned Canadian laboratory are seeking a clinical research group, hospital, or institute specializing in Parkinson's disease from an eligible European country (excluding France and Canada) to join their consortium.
Advantages and Innovations
With this project, the innovative approach of the French company and the Canadian laboratory will be as follows:
. Harmonize distributed clinical and neuroimaging datasets using federated learning.
. Train AI models across multiple clinical centers while maintaining patient data privacy.
. Integrate pharmacological modeling to predict treatment response in Parkinson's disease.
. Validate the AI-based recommendations in real-world clinical settings.
Technical Specification or Expertise Sought
The partner could be a clinical research institute, a neurology center, or an academic research group.

Expected role and expertise.
The ideal partner will:
Provide clinical expertise in the treatment and progression of Parkinson's disease.
Validate AI model results against real patient cases.
Provide anonymized clinical data for federated learning experiments.
Ensure the integration of AI-driven pharmacological recommendations into clinical workflows.

By participating in this initiative, the partner will be able to:
Access cutting-edge AI models for neurodegenerative disease research.
Shape the future of federated learning applications in neurology, and directly on Parkinson's disease.
Contribute to a high-impact international research consortium in the field of AI-driven precision medicine.
Stage of Development
  • Concept stage
Sustainable Development Goals
  • Goal 3: Good Health and Well-being

Partner Sought

Expected Role of a Partner
A. Role of the partner
1. Cooperation Type: Clinical research institute, neurology center, or academic research group
2. Location: Must be based in one of the eligible JPND countries (excluding France and Canada)
3. Required expertise:
- Clinical expertise in Parkinson's disease, with access to patient cohorts in the moderate to late stages
- Experience with longitudinal neurodegenerative disease studies involving neuroimaging and/or pharmacological interventions
- Knowledge of Parkinson treatments, the efficacies and second effects
Familiarity with clinical trial design or real-world data collection is a plus.

B.Tasks & Responsibilities
The selected partner will play a key role in validating AI-based models and ensuring their clinical applicability. Their responsibilities will include:
1. Providing clinical data for model training & validation
- Share anonymized patient data (clinical and neuroimaging) for federated learning experiments
- Ensure compliance with ethical, regulatory, and privacy standards for medical data sharing
- Support the adaptation of federated learning protocols to clinical workflows

2. Validating AI-generated pharmacological and treatment recommendations
- Assess the accuracy and clinical relevance of AI-based pharmacological treatment recommendations
- Compare AI-generated insights with current best practices in Parkinson's disease treatment
- Provide clinical feedback to refine AI models and federated learning pipelines

3. Leading work package on real-world AI deployment and validation
- Oversee a dedicated work package on clinical validation, ensuring AI models are evaluated on real patient data
- Participate in joint publications, dissemination, and reporting of findings to funding agencies
- Contribute to the development of guidelines for integrating AI-driven decision support tools into clinical settings
Type and Size of Partner
  • Other
  • R&D Institution
  • University
Type of partnership
  • Research and development cooperation agreement

Call details

Framework program
  • Joint Technology Initiatives
Call title and identifier
EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative
Submission and evaluation scheme
There will be a two-stage procedure for applications: pre-proposals and full-proposals. At both stages, one joint proposal document shall be prepared by the consortium and submitted by the coordinator.
Coordinator required
No
Deadline for EoI
Deadline of the call
Project duration in weeks
156
Web link to the call
https://neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/202…

Dissemination

Technology keywords
  • 06001015 - Pharmaceutical Products / Drugs
  • 06001014 - Neurology, Brain Research
  • 06001005 - Diagnostics, Diagnosis
  • 06003002 - Gene Expression, Proteome Research
  • 06001012 - Medical Research
Market keywords
  • 05001001 - Diagnostic services
  • 04016 - Population genetics
  • 02006004 - Data processing, analysis and input services
  • 04015 - Gene Expression, Proteome Research
Sector Groups Involved
  • Health
Targeted countries
  • All countries